?. , ?. Non-chez-vous, and ?. , A l'extérieur ? Seul ? En groupe ?, Plan d'action pour remédier aux carences Avez-vous une activité sportive régulière

.. Avez-vous-peur-de-tomber, ? oui ? non Avez-vous modifié l'aménagement de votre domicile ? ? oui ? non Si oui, de quelle façon ? Pour quelle raison ?

?. Savez-vous-combien-de-temps-il-faudra-le-prendre, Respectez vous les consignes de prise du médicament. ?

N. Patient and J. Pl, Prénom: __ A REMPLIR PAR LE PHARMACIEN lors de l'entretien à "aide du guide d'entretien ENTRETIEN PHARMACIEN

P. J. Meunier, L'ostéoporose. s.l, 2005.

J. Dadoune, P. Hadjiisky, J. Siffroi, and E. Vendrely, Histologie 2ème Ed. Paris. s.l. : Médecine science flammarion, 2000. 3. F. Pebret. Anatomie-physiologie-pharmacologie générale. 6ème Ed. s.l. : Paris, 2006.

J. Desoutter, R. Mentaverri, M. Brazier, and S. Kamel, Le remodelage osseux normal et pathologique, Revue Francophone des Laboratoires, vol.2012, issue.446
DOI : 10.1016/S1773-035X(12)71733-1

K. Henriksen, A. V. Neutzsky-wulff, L. F. Bonewald, and M. A. Karsdal, Local communication on and within bone controls bone remodeling, Bone, vol.44, issue.6, pp.1026-1033, 2009.
DOI : 10.1016/j.bone.2009.03.671

A. Taylor, M. Saunders, D. Shingle, J. Cimbala, Z. Zhou et al., Mechanically stimulated osteocytes regulate osteoblastic activity via gap junctions. Cell Physiology, 2007.
DOI : 10.1152/ajpcell.00611.2005

URL : http://ajpcell.physiology.org/content/ajpcell/292/1/C545.full.pdf

K. Clément and G. Karsenty, Neural control of bone remodeling: crucial role of leptin

J. David, C. Mellis, . Itzstein, H. Miep, . Helfrich et al., The skeleton: a multifunctional complex organ. The role of key signalling pathways in osteoclast differentiation and in bone resorption, Journal of Endocrinology, vol.211, pp.131-143, 2011.

A. Research, &. Therapy, J. C. Gallagher, and A. J. Sai, Molecular biology of bone remodeling: Implications for new therapeutic targets for ostoporosis, Maturitas, vol.13, issue.65, pp.301-307, 2010.

B. Zhao, B. Lionel, and . Ivashkiv, Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors, Arthritis Research & Therapy, vol.13, issue.4, p.234, 2011.
DOI : 10.1074/jbc.M501900200

W. J. Boyle, W. S. Simonet, and D. L. Lacey, Osteoclast differentiation 14. Mawer, Davies. Vitamin D Nutrition and Bone Disease in Adults Organisation Mondiale De La Santé. Evaluation du risque fracturaire et son application au dépistage de l'ostéoporose. Genève : s.n, Nature. Endocrine & Metabolic Disorders, vol.423, issue.15 16, pp.153-164, 1994.

. Groupe-de-recherche, Information sur les Ostéoporoses. Ostéoporoses. s.l. : Collection conduites Doin Le concours médical. Prévention, diagnostic et traitement de l'ostéoporose. Le concours médical, pp.33-34, 2005.

J. Center and J. Eisman, The epidemiology and pathogenesis of osteoporosis. Baillière's Clinical Endocrinology and Metabolism, 1997.

B. J. Gates, T. E. Sonnett, C. A. Duvall, E. K. Dobbins-mccloskey, H. Cawston-fardellone et al., Epidemiology, etiology, and diagnosis of osteoporosis Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. International Osteoporosis Foundation and National Osteoporosis Foundation 2012 Éric Lespessailles, François-Emery Cotté, Christian Roux Prevalence and features of osteoporosis in the French general population: The Instant study. Joint Bone Spine Osteoporosis: burden, health care provision and opportunities in the EU Epidemiology of osteoporosis-related fractures in France: A literature review, Prevalence of vertebral fractures in French women older than 75 years from the EPIDOS study Landais, C. Roux. Hospitalized wrist fractures in France:Incidence and burden trend changes. Orthopaedics & Traumatology: Surgery & Research, pp.34-63, 2004.

T. Thierry, A. C. La-prévention-de-la-première-fracture-ostéoporotique-tineke, and . Van-geel, Revue du Rhumatisme Timing of Subsequent Fractures after an Initial Fracture Organisation mondiale de la santé, -Yves Reginster. Utility Values Associated with Osteoporotic Fracture : A Systematic Review of the Literature, pp.118-122, 2007.

F. Borgstrom, N. Zethraeus, O. Johnell, L. Lidgren, S. Ponzer et al., Costs and quality of life associated with osteoporosis-related fractures in Sweden, Osteoporosis International, vol.7, issue.Suppl 2, pp.1-14, 2005.
DOI : 10.1007/s00198-005-0015-8

T. Peasgood, K. Herrmann, J. A. Kanis, and J. E. Brazier, An updated systematic review of Health State Utility Values for osteoporosis related conditions. International Osteoporosis Foundation and National Osteoporosis Foundation, pp.853-868, 2009.

M. Schwenkglenks, K. Lippuner, H. Hauselmann, T. D. Szucs, B. Häussler et al., A model of osteoporosis impact in Switzerland 2000???2020, Osteoporosis International, vol.29, issue.6, pp.659-671, 2000.
DOI : 10.1111/j.1532-5415.2000.tb02658.x

P. Fardellone, Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis, Joint Bone Spine, vol.77, issue.1, pp.53-57, 2009.
DOI : 10.1016/j.jbspin.2009.04.009

M. Maravic, C. L. Bihan, P. Landais, P. Fardellone, C. Rehnberg et al., Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database, Osteoporosis International, vol.13, issue.12, pp.1475-1480, 2001.
DOI : 10.1016/S0020-1383(99)00248-X

E. Mccloskey, H. Johansson, A. Oden, A. John, and . Kanis, Fracture risk assessment Société française de rhumatologie, GRIO. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, Clinical Biochemistry. 2012 Joint Bone Spine, vol.45, issue.79, pp.887-893, 2012.

. Haute-autorité-de-santé, Prévention, diagnostic et traitement, Note de synthèse, 2006.

C. David, Sévérité de l'ostéoporose : quel est l'impact des pathologies associées ? Revue du Rhumatisme, pp.43-46, 2010.

V. Breuil and L. Euller-ziegler, Nutrition et vieillissement osseux. L'ostéoporose. Nutrition clinique et métabolisme, pp.212-218, 2004.
DOI : 10.1016/j.nupar.2004.10.005

M. Yasser, A. N. Miedany, M. A. Mehanna, and . Baddini, Altered bone metabolism in patients with osteoarthritis, Joint Bone Spine, vol.67, pp.900-907, 2000.

M. Cohen-solal, M. De-vernejoul, and P. Orcel, Ostéoporose et diabète. Médecine & Longévité, pp.22-25, 2009.

J. C. Kreiger and . Prior, The Canadian Multicentre Osteoporosis Study Research Group Physical activity, body mass index and bone mineral density : associations in a prospective population-based cohort of women and men : The Canadian Multicentre Osteoporosis Study (CaMos), Bone. 2012, vol.50, pp.401-408

. Berntsen, Lifestyle impact on lifetime bone loss in women and men : The Tromsø Study, Bone, vol.44, pp.18-55, 2009.

J. Berdah, Intérêt d'une bonne hygiène dans la prévention de l'ostéoporose : le rôle du gynécologue. Gynécologie Obstétrique & Fertilité, pp.785-790, 2007.

O. Duygu-ozkale, Prolonged breast-feeding is an independent risk factor for postmenopausal osteoporosis, Maturitas. 2013, vol.74, pp.270-275

H. Hwansik, B. Jongmyon, H. Seungwook, P. Hoonki, and K. Inyoung, Les effets de??la??plong??e en??apn??e sur??la??densit?? min??rale osseuse des??femmes plongeuses, Revue du Rhumatisme, vol.73, issue.7, pp.711-715, 2006.
DOI : 10.1016/j.rhum.2005.07.005

A. Morrison, Epidemiology of falls and osteoporotic fractures : a systematic review ClinicoEconomics and Outcomes Research Sumapa Chaiamnuay, Kenneth G Saag. Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord, pp.9-18, 2006.

T. Thomas, V. Breuil, and K. Briot, Les bisphosphonates oraux dans??le??traitement de??l'ost??oporose postm??nopausique, Revue du Rhumatisme, vol.73, issue.8, pp.817-827, 2006.
DOI : 10.1016/j.rhum.2006.05.005

. Thériaque, . Monographie-du-risédronate, and . Thériaque, [En ligne] [Citation : 13 mai 2013.] http://www.theriaque.org/apps/monographie/index.php?type=SP&id=29129&info=CLASS. 62. Räkel. Role of zoledronic acid in the prevention and treatment of osteoporosis, Clinical Interventions in Aging, vol.6, pp.89-99, 2011.

S. Boonen, S. Ferrari, D. Paul, . Miller, F. Erik et al., Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective, Journal of Bone and Mineral Research, vol.95, issue.Suppl 1, pp.963-974, 2012.
DOI : 10.1210/jc.2009-1947

B. Abrahamsen, Adverse Effects of Bisphosphonates, Calcified Tissue International, vol.333, issue.6, pp.421-435
DOI : 10.1007/BF03346353

D. Thiébaud, An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass, Bone. 2012, vol.61, issue.50, pp.386-92, 1997.

B. Abrahamsen, M. Pazianas, P. Eiken, R. Russell, and R. Eastell, Esophageal and gastric cancer incidence and mortality in alendronate users, Journal of Bone and Mineral Research, vol.19, issue.6, pp.679-686, 1803.
DOI : 10.1007/s00198-007-0540-8

U. Syversen, Denosumab for behandling av postmenopausal osteoporose. Tidsskr Nor Legeforen, pp.1893-1896, 2011.

L. Silva-fernández, M. P. Rosario, J. A. Martínez-lópez, L. Carmonad, E. Loza-serge-ferrari et al., Denosumab for the treatment of osteoporosis: A systematic literature review Denosumab and bisphosphonates: Different mechanisms of action and effects, Reumatol Clin. 2013 Bone, vol.9, issue.72, pp.42-52, 2011.

M. Quemerais-durieu, V. Kerlan, and O. Chabre, Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab) Annals of endocrinology, pp.15-22, 2011.

K. Briot, F. Trémollières, T. Thomas, C. Roux, and G. , How long should patients take medications for postmenopausal osteoporosis? Revue du Rhumatisme, pp.27-34, 2007.

S. Barry, A. A. Komm, and . Chines, An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis, Maturitas. 2012, vol.71, pp.221-226

R. B. Wagman and P. D. Miller, The Use of Teriparatide and PTH(1-84) for the Treatment of Osteoporosis, Clinical Reviews in Bone and Mineral Metabolism, vol.4, issue.4, pp.277-290, 2006.
DOI : 10.1385/BMM:4:4:277

F. Debiais, Efficacy data on teriparatide (parathyroid hormone) in patients with postmenopausal osteoporosis, Joint Bone Spine, vol.70, issue.6, pp.836-841, 2003.
DOI : 10.1016/j.jbspin.2003.08.002

R. K. Dore, Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis, Patient Preference and Adherence, vol.7, pp.435-446
DOI : 10.2147/PPA.S31067

F. Debiais and G. Durand, Efficacy data on teriparatide (parathyroid hormone) in patients with postmenopausal osteoporosis, Joint Bone Spine, vol.70, issue.6, pp.836-841, 2003.
DOI : 10.1016/j.jbspin.2003.08.002

C. H. Chesnut, S. Silverman, K. Andriano, H. Genant, A. Gimona et al., A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. The american journal of medicine Treatment of postmenopausal osteoporosis. The American Society of Contemporary Medicine and Surgery, 2000.

P. Fardellone, F. Cotté, C. Roux, E. Lespessailles, and F. Mercier, Calcium intake and the risk of osteoporosis and fractures in French women, Joint Bone Spine, vol.77, issue.2, pp.154-158, 2010.
DOI : 10.1016/j.jbspin.2009.08.007

P. Fardellone, J. Sebert, M. Bouraya, O. Bonidan, G. Leclercq et al., Evaluation de la teneur en calcium du régime alimentaire par autoquestionnaire fréquentiel, Rev Rhum, vol.2, issue.58, pp.99-103, 1991.

. Thériaque, Monographie du calcium vitamine D 500mg/400ui. [En ligne, pp.22-30

P. J. Marie, php?type=SP&id=17572&info=COMPO. 91. ?. Monographie du ranelate de strontium. Thériaque. [En ligne] [Citation : 22 08 2013 Strontium signaling: Molecular mechanisms and therapeutic implications in osteoporosis, pp.216-226

E. Bonnelye, A. Chabadel, F. Saltel, and P. Jurdic, Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro Audrey Doublier, Delphine Farlay. Strontium ranelate ? a promising therapeutic principle in osteoporosis, 129. 94. Georges Boivina, pp.153-156, 2008.

M. Curiel, M. Brandi, J. Badurski, J. Wark, A. Balogh et al., Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis, Osteoporos Int. 2012, vol.3, pp.1115-1137

J. Rossouw, G. Anderson, R. Prentice, A. Lacroix, C. Kooperberg et al., Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal Results From the Women's Health Initiative Randomized Controlled Trial, Jama, vol.288, pp.321-354, 2002.

J. Hays, J. R. Hunt, F. A. Hubbell, G. L. Anderson, M. Limacher et al., The women's health initiative recruitment methods and results, Annals of Epidemiology, vol.13, issue.9, pp.18-77, 2003.
DOI : 10.1016/S1047-2797(03)00042-5

J. A. Simon, F. Lin, E. Vittinghoff, and V. Bittner, The Relation of Postmenopausal Hormone Therapy to Serum Uric Acid and the Risk of Coronary Heart Disease Events: The Heart and Estrogen???Progestin Replacement Study (HERS), Annals of Epidemiology, vol.16, issue.2, pp.138-145, 2006.
DOI : 10.1016/j.annepidem.2005.04.003

C. Ribot and F. Trémollières, Hormone replacement therapy in the management of postmenopausal osteoporosis and prevention of fracture risk 1557-63. 100. C. Ribot, F. Trémollieres. Hormone replacement therapy in postmenopausal women: all the treatments are not the same. Gynécologie Obstétrique & Fertilité, Presse Med, pp.388-397, 2006.

. Agence-nationale-de-sécurité-du-médicament, Traitement Hormonal de la Ménopause (THM) ANSM. [En ligne] [Citation : 12 08 2013.] http://ansm.sante.fr/S-informer/Presse- Communiques-Points-presse/Traitement-Hormonal-de-la-Menopause-THM/%28language%29/fre- FR. 102, Medical management following an osteoporotic fracture

&. Orthopaedics, H. Ha-vinh, L. Clavaud, and . Sauze, Caractéristiques individuelles et mortalité associées au traitement hormonal substitutif de la ménopause :étude d'une cohorte française de femmes d'âge compris entre 60 et 69 ans Journal de Gynécologie Obstétrique et Biologie de la Reproduction Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis : a five-year cross-sectional study with public health implications, C. De Jaeger, P. Cherin. Vitamin D : Effects on the health. Recommendations of good use, pp.860-869, 2001.

. Thériaque, Monographie de l'Uvedose. Thériaque. [En ligne] [Citation : 2013 08 12

J. Paccou, ??valuation du risque fracturaire au cours de l???ost??oporose post-m??nopausique en pratique clinique ?? l???aide du FRAX?? : place des marqueurs du remodelage osseux, Revue Francophone des Laboratoires, vol.2012, issue.446, pp.53-62
DOI : 10.1016/S1773-035X(12)71735-5

O. Philippe, E. Le-lewiecki, and . Michael, Aspects physiopathologiques et cliniques du vieillissement osseux. 2012. 110. Åkesson, Kristina. New approaches to pharmacological treatment of osteoporosis. Bulletin of the World Health Organization Sclerostin : A novel target for intervention in the treatment of osteoporosis Discovery Medecine, 2003.

E. Gregg, M. Pereira, and C. Caspersen, Physical Activity, Falls, and Fractures Among Older Adults: A Review of the Epidemiologic Evidence, Journal of the American Geriatrics Society, vol.80, issue.8, pp.883-93, 2000.
DOI : 10.2105/AJPH.80.7.871

A. Moayyeri, The Association Between Physical Activity and Osteoporotic Fractures: A Review of the Evidence and Implications for Future Research, Annals of Epidemiology, vol.18, issue.11, pp.827-835, 2008.
DOI : 10.1016/j.annepidem.2008.08.007

A. Moayyeria, H. Besson, R. N. Luben, N. J. Wareham, and K. Kha, The association between physical activity in different domains of life and risk of osteoporotic fractures, Bone, vol.47, issue.3
DOI : 10.1016/j.bone.2010.06.023

N. M. Schmitt, J. Schmitt, and M. Dören, The role of physical activity in the prevention of osteoporosis in postmenopausal women???An update, Maturitas, vol.63, issue.1, pp.34-38, 2009.
DOI : 10.1016/j.maturitas.2009.03.002

T. Howe, B. Shea, L. Dawson, F. Downie, A. Murray et al., Exercise for preventing and treating osteoporosis in postmenopausal women Nonpharmacological prevention of osteoporotic fractures, Cochrane Database of Systematic Reviews Joint Bone Spine, vol.7, issue.70, pp.448-457, 2003.

B. J. Gates, T. E. Sonnett, C. A. Duvall, and E. K. Dobbins, Review of osteoporosis pharmacotherapy for geriatric patients, The American Journal of Geriatric Pharmacotherapy, vol.7, issue.6, pp.293-323, 2009.
DOI : 10.1016/j.amjopharm.2009.12.004

G. Sarah, O. De-la-république, and . Française, Prise en charge du transplanté d'organe : Visions croisées des pharmaciens d'officine et des patients et mise en place d'entretiens pharmaceutiques. Nancy : Thèse pharmacie, 31 mai 2013, Journal officiel de la république francaise. Décret n° 2010-906 du 2 août 2010 relatif aux compétences requises pour dispenser l'éducation thérapeutique du patient

E. Lespessailles, V. Martaillé, and C. Beauvais, Besoins et objectifs éducatifs des patients atteints d'ostéoporose. Revue du rhumatisme monographies, pp.157-161, 2013.
DOI : 10.1016/j.monrhu.2013.04.005

K. G. Roux, P. Saag, S. Sambrook, N. B. Silverman, and . Watt, Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)

L. Giangregorio, A. Papaioannou, A. Cranney, N. Zytaruk, and J. Adachi, Fragility Fractures and the Osteoporosis Care Gap: An International Phenomenon, Seminars in Arthritis and Rheumatism, vol.35, issue.5, pp.293-305, 2006.
DOI : 10.1016/j.semarthrit.2005.11.001

M. Ashe, K. Khan, P. Guy, K. Kruse, K. Hughes et al., Wristwatch???distal radial fracture as a marker for osteoporosis investigation:, Journal of Hand Therapy, vol.17, issue.3, pp.324-328, 2004.
DOI : 10.1197/j.jht.2004.04.001

B. Cortet and O. Bénichou, Adherence, compliance, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine, pp.1-9, 2006.

J. Sampalis, J. Adachi, E. Rampakakis, J. Vaillancourt, A. Karellis et al., Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence, Journal of Bone and Mineral Research, vol.20, issue.8, pp.202-212
DOI : 10.1007/s00198-008-0795-8

B. Briesacher, S. Andrade, R. Yood, and K. Kahler, Consequences of poor compliance with bisphosphonates. Bone, pp.882-889, 2007.

J. R. Curtis, Q. Cai, S. W. Wade, B. S. Stolshek, J. L. Adams et al., Osteoporosis medication adherence: Physician perceptions vs. patients' utilization Development and pilot testing of a decision aid for postmenopausal women with osteoporosis, Bone. Patient Educ Couns, vol.2013, issue.47, pp.1-6, 2002.
DOI : 10.1016/j.bone.2013.03.003

URL : http://europepmc.org/articles/pmc3777338?pdf=render

J. Walliser-duarte, S. C. Bolge, and S. S. Sen, An evaluation of patients' preferences for osteoporosis medications and their attributes: The PREFER-International Study

A. H. Warriner and J. R. Curtis, Adherence to osteoporosis treatments: room for improvement, Current Opinion in Rheumatology, vol.21, issue.4, pp.356-362, 2009.
DOI : 10.1097/BOR.0b013e32832c6aa4

E. V. Mccloskey, Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis, Maturitas, vol.237, pp.75-81, 2000.

C. Lorish, J. Parker, and S. Brown, Effective patient education. A quasi-experiment comparing an individualized strategy with a routinized strategy, Arthritis & Rheumatism, vol.4, issue.11, pp.1289-97, 1985.
DOI : 10.1001/archpsyc.1961.01710120031004

M. Hiligsmann, M. Salas, D. Hughes, E. Manias, F. Gwadry-sridhar et al., Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group, Osteoporosis International, vol.73, issue.236
DOI : 10.1111/j.1365-2125.2012.04167.x

. Pasco, General medical practitioners' knowledge and beliefs about osteoporosis and its investigation and management, Arch Osteoporos. 2012, vol.7, pp.107-121

W. Li and D. Kendler, Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information1, Journal of Clinical Pharmacy and Therapeutics, vol.27, issue.6, pp.531-537, 2004.
DOI : 10.1016/S0160-3450(16)33864-8

K. Hansen, E. Rosenblatt, C. Gjerde, and M. Crowe, Can an Online Osteoporosis Lecture Increase Physician Knowledge and Improve Patient Care?, Journal of Clinical Densitometry, vol.10, issue.1, pp.10-20, 2007.
DOI : 10.1016/j.jocd.2006.10.001

A. Horan and F. Timmins, The role of community multidisciplinary teams in osteoporosis treatment and prevention, Journal of Orthopaedic Nursing, vol.13, issue.2, pp.85-96, 2009.
DOI : 10.1016/j.joon.2009.03.003

J. C. Barner and A. Branvold, Patients' willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations. Research in Social and Administrative Pharmacy, pp.77-100, 2005.

P. Lai, S. Chua, Y. Chew, and S. Chan, Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women, Journal of Clinical Pharmacy and Therapeutics, vol.32, issue.Suppl. 6, pp.557-67, 2011.
DOI : 10.1016/S8756-3282(03)00091-7

P. Lai, S. Chua, and S. Chan, Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis, International Journal of Clinical Pharmacy, vol.32, issue.18, pp.629-666
DOI : 10.1097/BRS.0b013e318133fb82

. Ordre-des-pharmaciens, Comment déployer la prescription électronique. Ordres des pharmaciens. [En ligne] [Citation : 22 08 2013/Communications/Rapports-Publications-ordinales/E-prescription- comment-deployer-la-prescription-electronique

N. Yuksel, S. Majumdar, C. Biggs, and R. Tsuyuki, Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial, Osteoporosis International, vol.10, issue.2, pp.391-399
DOI : 10.1503/cmaj.070981

Y. Liu, J. Nevins, K. Carruthers, W. Doucette, R. Mcdonough et al., Osteoporosis risk screening for women in a community pharmacy, Journal of the American Pharmacists Association, vol.47, issue.4, pp.521-527, 2003.
DOI : 10.1331/JAPhA.2007.05107

T. Gleeson, M. Iversen, J. Avorn, A. Brookhart, J. Katz et al., Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review PAO13: United states community pharmacists' interventions with female patients regarding osteoporosis, Osteoporos Int. Value in Health ALCOV. Ostéoporose. ALCOV. [En ligne], vol.20, issue.487 151, pp.2127-2161, 2001.

. Groupe-de-recherche, Information sur les Ostéoporoses GRIO Ostéoporama : les diaporamas par thèmes. GRIO. [En ligne] 21 01 2012. [Citation : 08 07 2013